Product Name: Recombinant Human Factor IX (C-6His)
Catalog #: PHH0613

Summary

Name	Coagulation factor Ix chain/F9
Purity	Greater than 95% as determined by reducing SDS-PAGE
Endotoxin level	<1 EU/μg as determined by LAL test.
Construction	Recombinant Human Coagulation Factor IX is produced by our Mammalian expression system and the target gene encoding Thr29-Thr461 is expressed with a 6His tag at the C-terminus.
Accession #	P00740
Host	Human Cells
Species	Human
Predicted Molecular Mass	49.8 KDa
Formulation	Supplied as a 0.2 μm filtered solution of 20mM Tris-HCl, 150mM NaCl, 10% Glycerol, pH 8.0.
Shipping	The product is shipped on dry ice/polar packs. Upon receipt, store it immediately at the temperature listed below.
Stability&Storage	Store at ≤-70°C, stable for 6 months after receipt. Store at ≤-70°C, stable for 3 months under sterile conditions after opening. Please minimize freeze-thaw cycles.
Reconstitution	

SDS-PAGE image

Product Name: Recombinant Human Factor IX (C-6His)
Catalog #: PHH0613



Alternative Names

F9; Coagulation factor IX; Christmas factor;Plasma thromboplastin component; Coagulation factor IXa light chain; Coagulation factor IXa heavy chain

Background

Coagulation factor IX (F9), is a member of the peptidase S1 family. It contains two EGF-like domains, a Gla domain and a peptidase S1 domain. It is primarily expressed in the liver and secreted in plasma. Factor IX is a vitamin K-dependent plasma protein that participates in the intrinsic pathway of blood coagulation by converting factor X to its active form in the presence of Ca2+ ions, phospholipids, and factor VIIIa. Mutations in position 43 and 46 prevents cleavage of the propeptide, mutation in position 93 probably fails to bind to cell membranes, mutation in position 191 or in position 226 prevent cleavage of the activation peptide. Mutations of human F9 can result in thrombophilia and recessive X-linked hemophilia B (HEMB). An X-linked blood coagulation disorder characterized by a permanent tendency to hemorrhage, due to factor IX deficiency. It is phenotypically similar to hemophilia A, but patients present with fewer symptoms. Many patients are asymptomatic until the hemostatic system is stressed by surgery or trauma.

Note

For Research Use Only , Not for Diagnostic Use.